143 related articles for article (PubMed ID: 21782059)
41. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
43. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
44. Prognostic relevance of clinical risk factors in mantle cell lymphoma.
Hoster E
Semin Hematol; 2011 Jul; 48(3):185-8. PubMed ID: 21782060
[TBL] [Abstract][Full Text] [Related]
45. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
[TBL] [Abstract][Full Text] [Related]
46. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
Wu X; Lu H; Pang T; Li X; Luo H; Tan H; Liu S
Leuk Res; 2021 Sep; 108():106605. PubMed ID: 34090063
[TBL] [Abstract][Full Text] [Related]
47. Advances in the assessment of minimal residual disease in mantle cell lymphoma.
Jung D; Jain P; Yao Y; Wang M
J Hematol Oncol; 2020 Sep; 13(1):127. PubMed ID: 32972438
[TBL] [Abstract][Full Text] [Related]
48. Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
Herrera AF; Armand P
J Clin Oncol; 2017 Dec; 35(34):3877-3887. PubMed ID: 28933999
[TBL] [Abstract][Full Text] [Related]
49. Minimal residual disease testing in hematologic malignancies and solid cancer.
Ben Lassoued A; Nivaggioni V; Gabert J
Expert Rev Mol Diagn; 2014 Jul; 14(6):699-712. PubMed ID: 24938122
[TBL] [Abstract][Full Text] [Related]
50. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
[TBL] [Abstract][Full Text] [Related]
51. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance.
Ladetto M; Tavarozzi R; Pott C
Hematol Oncol Clin North Am; 2020 Oct; 34(5):887-901. PubMed ID: 32861285
[TBL] [Abstract][Full Text] [Related]
52. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
Ferrero S; Grimaldi D; Genuardi E; Drandi D; Zaccaria GM; Alessandria B; Ghislieri M; Ferrante M; Evangelista A; Mantoan B; De Luca G; Stefani PM; Benedetti F; Casaroli I; Zanni M; Castellino C; Pavone V; Petrini M; Re F; Hohaus S; Musuraca G; Cascavilla N; Ghiggi C; Liberati AM; Cortelazzo S; Ladetto M
Blood; 2022 Sep; 140(12):1378-1389. PubMed ID: 35737911
[TBL] [Abstract][Full Text] [Related]
53. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
Hoster E; Pott C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
[TBL] [Abstract][Full Text] [Related]
54. Technical issues: flow cytometry and rare event analysis.
Hedley BD; Keeney M
Int J Lab Hematol; 2013 Jun; 35(3):344-50. PubMed ID: 23590661
[TBL] [Abstract][Full Text] [Related]
55. Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel 8-Color Flow Cytometry Approach.
Chovancová J; Bernard T; Stehlíková O; Sálek D; Janíková A; Mayer J; Doubek M
Cytometry B Clin Cytom; 2014 Nov; ():. PubMed ID: 25430636
[TBL] [Abstract][Full Text] [Related]
56. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis.
Zhou Y; Chen H; Tao Y; Zhong Q; Shi Y
J Cancer; 2021; 12(2):553-561. PubMed ID: 33391451
[No Abstract] [Full Text] [Related]
57. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
Ferrero S; Dreyling M;
Haematologica; 2017 Jul; 102(7):1133-1136. PubMed ID: 28655809
[No Abstract] [Full Text] [Related]
58. Predicting the future in MCL with MRD.
Blombery P; Cheah CY
Blood; 2022 Sep; 140(12):1332-1333. PubMed ID: 36136360
[No Abstract] [Full Text] [Related]
59. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.
Lobetti-Bodoni C; Mantoan B; Monitillo L; Genuardi E; Drandi D; Barbero D; Bernocco E; Boccadoro M; Ladetto M
Ther Adv Hematol; 2013 Jun; 4(3):189-98. PubMed ID: 23730496
[TBL] [Abstract][Full Text] [Related]
60. Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.
Drandi D; Alcantara M; Benmaad I; Söhlbrandt A; Lhermitte L; Zaccaria G; Ferrante M; Genuardi E; Mantoan B; Villarese P; Cheminant M; Starza ID; Ciabatti E; Bomben R; Jimenez C; Callanan M; Abdo C; Eckert C; Ribrag V; Cortelazzo S; Dreyling M; Hermine O; Delfau-Larue MH; Pott C; Ladetto M; Ferrero S; Macintyre E
Hemasphere; 2020 Apr; 4(2):e347. PubMed ID: 32309784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
